All In Biotech

Drug Trial Radar · NCT00883532

Prevention of Chronic Lung Disease (CLD) in Preterm Infants

Prevention of Chronic Lung Disease (CLD) in Preterm Infants -A New Therapeutic Regimen

Last checked: Nov 19, 2026Latest source record: Aug 8, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

300

Planned (sponsor's estimate)

Start

Apr 2009

Primary completion

Dec 2012

Study completion Apr 2013

Sponsor

Lead sponsor
China Medical University, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Taiwan University Hospital; Taipei Medical University Hospital; Cathay General Hospital; Chang Gung Memorial Hospital
First posted
Apr 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (care provider, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 30 minutes, up to 4 hours
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pulmonary inflammation plays an important role in the early development of CLD. Postnatal glucocorticoids have been shown effective in the prevention or treatment of CLD with various success. However, systemic glucocorticoid therapy often associated with various short term and long term complications. Therefore, modification of the therapeutic regimen is needed. Inhaled steroid, including inhaled budesonide,have been tried but the results are essentially unsuccessful, most likely due to small airways that the inhaled steroid reaching to the peripheral lungs are limited and unpredictable. Direct instillation of budesonide into the airway has also shown to be ineffective, possibly due to poor distribution of steroid in the lungs. The investigators hypothesize that intratracheal instillation of budesonide, a strong tropical steroid, using surfactant as vehicle would facilitate the delivery of budesonide to the lung periphery and would inhibit lung inflammation and improve the pulmonary outcome. The result of our pilot study (Pediatrics, 2008) indicated this high possibility.

Conditions

  • Respiratory Distress Syndrome
  • Chronic Lung Disease of Prematurity

Interventions

  • budesonideDrug

    budesonide, 0.25 mg/Kg/dose every 8 hours until the infant requires FIO2 \< 30% or is extubated

  • surfactant and air (placebo)Drug

    receive surfactant and air as control through endotracheal route

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Chronic lung disease morbidity among the survivalTime frame: 36 postconceptional weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China Medical University

    Taichung, Taiwan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.